DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Alonso S, Riveiro-Barciela M, Fernandez I. , et al.
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
J Viral Hepat 2017;
24 (04) 304-311
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.